Behold the Closest Images of the Sun Ever Taken
During its flyby, Parker snapped some amazing close-up images of the Sun, which NASA finally released to the public yesterday. The images, captured by the probe's Wide-Field Imager for Solar Probe, or WISPR, present an extraordinary view of the Sun's corona, buffeted by raging solar winds.
The snapshots capture a particularly intriguing moment for solar weather, in which not one but multiple coronal mass ejections (CMEs)—large outbursts of charged particles that affect space weather—are shown colliding at the periphery of the Sun's magnetic field.
'In these images, we're seeing the CMEs basically piling up on top of one another,' said Angelos Vourlidas, an engineer involved in WISPR at the Johns Hopkins Applied Physics Laboratory, in a statement. 'We're using this to figure out how the CMEs merge together, which can be important for space weather.'
The new images also provide a high-resolution view of solar wind activity, which NASA's scientists will likely use to refine their space weather prediction abilities.
'Parker Solar Probe has once again transported us into the dynamic atmosphere of our closest star,' said Nicky Fox, associate administrator, Science Mission Directorate at NASA Headquarters, in the same statement. 'This new data will help us vastly improve our space weather predictions to ensure the safety of our astronauts and the protection of our technology here on Earth and throughout the solar system.'
'The data that will come down from the spacecraft will be fresh information about a place that we, as humanity, have never been,' said Joe Westlake, director for NASA's Heliophysics Division, in a release published after last year's flyby.
The next big milestone for Parker will happen later this year on September 15, when the probe performs another close pass. With each new orbit, Parker is steadily uncovering the many unknown characteristics of the Sun. Each flyby is a reminder of how much we still don't know about our own host star—yet, at the same time, a reminder of how far we've come.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
12 minutes ago
- Medscape
Volume Fueling Rise in Part D Specialty Derm Drug Spending
Prescription volume for specialty medications, not price hikes, largely seems to be the main factor in the ongoing huge increase in Medicare Part D dermatology drug spending, according to a new study. Harvard Medical School researchers reported that from 2013 to 2022, prices were higher and rose faster for specialty medications, but that 80% of the increase in spending 'was due to increased prescriptions, not prices.' Price increases only accounted for 20% of the total growth in Medicare Part D dermatologic drug spending during the study period, lead author Edward L. Kong, PhD, told Medscape Medical News . Specialty medications — primarily immunomodulators — 'are just very expensive in general,' and are being rapidly adopted by clinicians, which is driving increased spending, said Kong, who is pursuing an MD degree at the Harvard-MIT Health Sciences and Technology program. Kong and Arash Mostaghimi, MD, MPA, MPH, medical director of the dermatology consult service at Brigham and Women's Hospital, and associate professor, Harvard Medical School, both in Boston, published their findings in JAMA Dermatology on July 16. They examined some 95 million prescriptions for Medicare beneficiaries, written by almost 25,000 dermatologists and dermatology-focused advanced practice clinicians. Inflation-adjusted spending increased an average of 16% a year, reaching $2.95 billion in 2022. Over the study time period, specialty drug spending increased just under 30% a year, reaching $2.4 billion in 2022. Spending on nonspecialty medications only grew 0.7% annually during the study period. By 2022, specialty medications accounted for 81% of all dermatology drug spending, having risen from a third of spending in 2013. Even so specialty medications only represented about 3% of all Medicare Part D dermatology prescriptions in 2022. Four of the specialty drugs were introduced before 2013: adalimumab (Humira), etanercept (Enbrel), ustekinumab (Stelara), and vismodegib (Erivedge). Six came on the market after 2013: apremilast (Otezla), secukinumab (Cosentyx), ixekizumab (Taltz), dupilumab (Dupixent), guselkumab (Tremfya), risankizumab-rzaa (Skyrizi), and sonidegib (Odomzo). The older medications had higher price growth than the six newer therapies during the study period. Humira, at the high end, had a 12% price increase per year, while Skyrizi, at the low end, had a 5% yearly decrease. It's possible that biosimilars for Humira and Stelara — introduced in 2023 and this year — might help restrain cost growth, wrote Kong and Mostaghimi. The introduction of generic oral JAK inhibitors such as tofacitinib may also put a dent in spending, they noted. Medicare will also likely achieve cost savings in 2026 on Enbrel and Stelara, which are included as part of a law — the Inflation Reduction Act— that gave the health program the power to negotiate prices of certain medications. Patients for affordable drugs now estimate that list prices for Enbrel will drop from around $7000 to $2355 and for Stelara from $13,836 to $4695. The study did not examine the value of the high-cost specialty drugs, but the rise in prescriptions — indicated by each of the 10 achieving a 1% market share — shows that the medications are being embraced, wrote Kong and Mostaghimi. The authors' work is similar to other studies that have documented major increases in Medicare Part D dermatologic drug spending being driven in part by increased adoption of specialty medications. A 2022 study in the Journal of the American Academy of Dermatology found that from 2013 to 2019, the price of six dermatology drugs in the top 10 most-prescribed medications decreased, mostly among nonspecialty medications. But in 2013, Enbrel was the most expensive medication in the top 50 most prescribed. Enbrel had been replaced in 2019 by Humira. In 2020, researchers reported in the Journal of Dermatological Treatment that annual spending on immunomodulator medications by Medicare Part D increased 303% from $1.7 billion in 2012 to $6.9 billion in 2018. 'Immunomodulator spending is growing and may be more substantial than previously reported posing significant burden on patients and the health system,' the authors wrote. Kong and Mostaghimi agreed, writing that 'the growing significance of specialty medications will have important implications for healthcare costs and patient affordability.' Kong reported receiving grants from the National Institute on Aging. Mostaghimi reported receiving personal fees from Hims & Hers Health, AbbVie, Sun Pharma, Digital Diagnostics, Eli Lilly, Equillium, ASLAN Pharmaceuticals, Boehringer Ingelheim, Figure 1, Indomo, Olaplex, Legacy Healthcare, Pelage, Q32 Bio, Astria Therapeutics, ACOM Health, Bioniz, Concert, and Digital Diagnostics; equity from ACOM Health, Figure 1, and Hims & Hers Health; licensing or royalties from Concert and Pfizer; and research funding from Aclaris, Concert, Eli Lilly, and Incyte outside the submitted work.
New York Times
13 minutes ago
- New York Times
My Teacher Is a Robot. Wait Till You Meet My Mom.
Two new graphic novels for kids feature alien beings that aren't what they seem. One is a monster disguised as a helper. The other is a monster that turns out not to be monstrous after all. In SCHOOLBOT 9000 (Dial, 288 pp., $14.99, ages 9 to 12), the first-time graphic novelist Sam Hepburn skewers artificial intelligence and the people hustling to sell it to us. Hepburn, a former tech writer, has built a near-future world full of robotic helpers that include taxi drivers, public safety officers, companions and pets. Just about everybody is awed by this shiny technology, burnished with retro design to appear friendly. But James, an 11-year-old with an artistic bent, prefers a more natural world. He got his skepticism from his father, who once told him that robots aren't 'just cold metal. They're cold — here,' and touched his heart. Dad has since died, and Mom has bought a HOMEBOT 3000 to help her manage the house and her busy career. As if a nattering robot at home weren't bad enough, James's school is taking part in a pilot program to introduce A.I. education via the SCHOOLBOT 9000. (Science-fiction-inclined parents will recognize the reference to HAL 9000, the murderous computer in '2001: A Space Odyssey.') Hepburn devotes loving attention to the ways in which human teachers connect with their students and give them confidence. By contrast, the A.I. educators ridicule the kids' artwork and music practice, even breaking one child's violin. 'Studies show that exposure to poor quality music is detrimental to brain structure, and may lead to cognitive and behavioral problems,' the SCHOOLBOT spouts. Cold indeed. They excel at some things. A lesson on Mesopotamia delivered by a human substitute teacher falls flat, so a SCHOOLBOT steps in with an impromptu rap: 'Stories and laws, math and much more, they inscribed it all, yeah, they built the core, in cuneiform script, forever they store! … Mesopotamia-mania! Feel the knowledge rain-ia!' The kids are entertained, but did they learn anything? Bit by bit, the budget-squeezed school kicks out the human teachers, which was the plan all along. The robots' big, evil manufacturer, Bux Global, is in cahoots with the paid-off mayor to make sure the pilot program succeeds at any cost. But the robots are glitchy, and the company's prejudices play out in the lessons. The arts and humanities are useless, one SCHOOLBOT contends: 'I am unable to find job descriptions that require specific knowledge of literary works such as 'Romeo and Juliet.'' They sort the kids into binary categories of tech work: 'creation' or 'maintenance.' The first group will be the programmers and designers; the others will keep the creations running. No reason to think about other professions, the robot sniffs: 'By the time you leave school, it is highly probable that your preferred job will already be performed by A.I.' Gee, it's almost as if Sam Altman were in the room. The students rebel. They enlist their parents. The SCHOOLBOT program is suspended. Freethinkers, rebels and techno-skeptics will find a lot to love here. Others might consider the book preachy and didactic. But tension builds again at the end as Bux Global performs an automatic software update on all its homebots: James's family's HOMEBOT 3000 suddenly reboots as the SCHOOLBOT Homeschooling System. Will the evil corporation take over education after all? And maybe the planet? Stay tuned: This is the first installment of a promised series. In DEEPLY DAVE (Holt, 240 pp., $14.99, ages 8 to 12), Michael Grover gives us a weird treat. Dave is a young explorer who's looking for his mother, an astronaut whose spaceship has gone missing in the depths of the ocean. (OK, that part doesn't really make sense. Keep going.) The delight of this book — a vertical rectangle bound at the top — is its format: Each flipped page takes you deeper, as if you're scrolling down a screen. That unusual design mimics the story's origins in the unfolding episodes of a webcomic (which in this case blinks and jitters, thanks to Grover's animation wizardry). Undersea creatures warn Dave that he's about to encounter 'the Big Doom.' He doesn't know what they're talking about, except that it's gigantic and powerful. But Dave isn't powerless. He's brought a pocketknife (which he shows to everyone he meets) and he makes friends along the way, including Amos, a shrimplike 'scavenger and entre-pruner' who's willing to help, in return for the quality seating inside Dave's mother's spaceship. (He craves a commode.) In a wry Freudian twist, the monster turns out to be … dun, dun, dun … Dave's mother, possessed by an alien creature she was studying — whom she inadvertently enraged by being callous about its egg. So the rescue mission gets a bit complicated, especially after an octopus, which used to be human, body-swaps with Dave to get its humanity back. Minds are melded. Bodies re-swap. The power of love saves the day. Ultimately, Dave's mother re-emerges, still gigantic but demonstrating a new empathy for the alien creature, with whom she's now fully symbiotic: 'She might be a cosmic being from another galaxy, and I might be an accomplished human astronaut … but at the end of the day we're just a couple of moms, trying to do right by our kids.'
Yahoo
an hour ago
- Yahoo
Should You Forget Tesla and Buy This Millionaire-Maker Stock Instead?
Key Points Shares of Rocket Lab USA have soared more than 50% year to date. The rise of space infrastructure is a long-term trend now unfolding. It will pick up speed as space travel becomes cheaper and more reliable. 10 stocks we like better than Rocket Lab › Is it time to move on from Tesla stock? After the first six months of 2025, many investors might be tempted to do so. As of this writing, shares of the electric vehicle maker are down 22%, leaving many investors very disappointed. While I'm not prepared to move on from Tesla, there are other innovative companies that investors should keep an eye on. Today, I want to cover one of them, Rocket Lab USA (NASDAQ: RKLB). Unlike Tesla, its shares have been on fire so far this year, with a year-to-date return of more than 60%. Here's what you need to know about the company and its stock. Rocket Lab USA The first question investors should ask is: What exactly does Rocket Lab USA do? Well, it's a leader in the field of rocketry and orbital deployments. The company partners with governmental and commercial organizations to send up satellites and other space-based assets into orbit. Like its better-known competitor, SpaceX, Rocket Lab is riding a fast-growing trend: the expansion of space infrastructure. In short, the need for more high-tech equipment in space is increasing as governments and businesses alike turn skyward. Everything from logistics tracking to farming can now incorporate orbital technology, and Rocket Lab is stepping up by expanding access to orbital launches. The company has already completed 10 successful launches of its Electron rocket this year, bringing its total to 68 overall. What's more, the company is progressing toward the use of its reusable Neutron rocket. That program aims to further expand Rocket Lab's overall launch profile by incorporating a reusable rocket (Neutron), which then lands on a 400-foot landing platform. By integrating reusable rocketry, RocketLab aims to lower launch costs, making space-based infrastructure more affordable -- and appealing -- to a growing list of organizations. As the company continues to ramp up launches, its financials are poised to improve. Over the past 12 months, Rocket Lab has generated $466 million in revenue, up 32% year over year. As the company's Neutron program comes online, Rocket Lab's revenue growth should accelerate. According to consensus estimates compiled by Yahoo! Finance, sell-side analysts expect Rocket Lab to generate $890 million in revenue in 2026, up 55% from 2025. Yet, investors should know that Rocket Lab stock does carry risks. For starters, the company is unprofitable and lacks positive free cash flow. Second, any setback in its operations due to a launch malfunction could delay future missions, putting pressure on the company's balance sheet. While Rocket Lab has over $428 million in cash on hand, it also has $490 million in debt. That means the company may need to raise further capital to service its debt and continue operations. Therefore, Rocket Lab stock isn't for every investor. As a high-flying stock -- in every sense of the phrase -- Rocket Lab may be too hot to handle for some investors. Nevertheless, for investors who are willing to hold through volatility, Rocket Lab offers a chance to invest in the next great adventure for humankind: space. It's clear that humanity will want to achieve more in space in the decades to come, and for that to happen, reliable and cheap transportation to space will be necessary. Rocket Lab is well-positioned to be one of the early leaders in this field. Investors should take notice. Should you buy stock in Rocket Lab right now? Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,281!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,050,415!* Now, it's worth noting Stock Advisor's total average return is 1,059% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Jake Lerch has positions in Rocket Lab and Tesla. The Motley Fool has positions in and recommends Rocket Lab and Tesla. The Motley Fool has a disclosure policy. Should You Forget Tesla and Buy This Millionaire-Maker Stock Instead? was originally published by The Motley Fool Sign in to access your portfolio
